Pharmaceutical sponsor
Tasly Pharmaceutical Group Co., Ltd Clinical Trials
Studies where Tasly Pharmaceutical Group Co., Ltd is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 14Heart Failure
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
This trial will evaluate the efficacy and safety of Qishen Yiqi Dripping Pills in treatment of Chronic Heart Failure with reduced ejection fraction resorted from Coronary Heart Disease (Syndrome of Qi Deficiency with Blood…
- Trial name
- NCT07687186
- Testing
- Qishen Yiqi Dripping Pills 2 bags
- Where
- 60 sites in China
- Volunteers
- 636 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Acute Ischemic Stroke
A Study of B2065 in Patients With Acute Ischemic Stroke
The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke.
- Trial name
- NCT07371624
- Testing
- B2065
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
AMD
A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD
The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.
- Trial name
- NCT07269769
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Depression
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
- Trial name
- NCT07485595
- Testing
- JS1-1-01 low-dose group, JS1-1-01 high-dose group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Metastatic Castration-Resistant Prostate Cancer Patients
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy
TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd. for solid tumor treatment.
- Trial name
- NCT07514065
- Testing
- Treatment arm: TSL2109 capsules。Oral administration。
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Recurrent Glioblastoma IDH Wildtype
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
This is an open-label, single-arm, dose-escalation and expansion Phase 1/2 clinical trial designed to evaluate the safety, tolerability and efficacy of P134 cells in patients with recurrent glioblastoma, to explore the maximum…
- Trial name
- NCT07318818
- Testing
- P134 cell injection
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Postprandial Distress Syndrome
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
The goal of this clinical trial is evaluating the efficacy and safety of Lianxiaxiaopi Granules in participant population. The main questions it aims to answer are: 1.
- Trial name
- NCT06696261
- Testing
- Lianxiaxiaopi Granules, a simulated agent of Lianxiaxiaopi Granules
- Where
- 18 sites in China
- Volunteers
- 342 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater…
- Conditions
- Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure, Chronic Ischemic Cardiomyopathy
- Trial name
- NCT07265349
- Testing
- Mesenchymal stem cells(HucMSCs), CABG
- Where
- 4 sites in China
- Volunteers
- 51 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Cough
Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment
To confirm the effect of Susu Xiaoer Zhike granules in treating cough caused by common cold (wind-cold cough Syndromes) in children aged 6~13 years, shortening the course of disease and improving symptoms.
- Trial name
- NCT06773117
- Testing
- Susu Xiao'er Zhike Granules, Extremely-low dose Susu Xiao'er Zhike Granules
- Where
- 19 sites in China
- Volunteers
- 360 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Diarrhea-predominant Irritable Boewl Syndrome
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
This study will evaluate the efficacy and safety of Changkang granules in the treatment of irritable bowel syndrome with predominant Diarrhea ( Liver qi affecting the spleen pattern)
- Trial name
- NCT06753890
- Testing
- Changkang granules
- Where
- 30 sites in China
- Volunteers
- 520 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd